NHP BehaviorAtlas Webinar | 3D NHP Behavioral Tracking For Drug Development - News

NHP BehaviorAtlas: High-Fidelity 3D NHP Behavioral Tracking

Transform complex non-human primate behaviors into quantitative, traceable, and translational drug development endpoints.

📅 Wednesday August 5, 2026

Register Now

Behavioral endpoints are among the most clinically relevant readouts in non-human primate studies. From scratching, pain responses, gait changes, hand movements, facial expressions, and disease-related activity patterns, NHP behaviors often provide direct functional evidence of disease progression and therapeutic response.

However, traditional behavioral assessment still relies heavily on manual observation, video review, and subjective scoring. These approaches can be time-consuming, labor-intensive, difficult to standardize, and limited in their ability to capture subtle or long-term behavioral changes.

In this joint webinar, Prisys and Bayone will introduce NHP BehaviorAtlas, a high-fidelity 3D NHP behavioral tracking platform designed to support modern preclinical drug development. By integrating multi-view video capture, 3D markerless pose estimation, behavioral kinematics, optic flow analysis, automated behavior classification, and disease model-specific behavioral databases, NHP BehaviorAtlas enables researchers to convert complex NHP behaviors into objective, quantitative, and actionable data.

The webinar will highlight how digital behavioral phenotyping can support drug efficacy evaluation across CNS disorders, pruritus, pain, dermatology, neurodegenerative diseases, gene therapy, and long-term translational studies.

Save Your Seat

Key Topics

The limitations of manual NHP behavioral observation and video scoring
How high-fidelity 3D NHP tracking enables objective behavioral quantification
Multi-view capture, 3D markerless pose estimation, and behavioral kinematics
Automated analysis of scratching behavior in NHP pruritus studies
3D Grimace Scale and facial expression analysis for pain and discomfort assessment
Hand, gait, posture, and activity tracking in CNS disease models
Longitudinal behavioral monitoring for drug efficacy and disease progression studies
How Prisys and Bayone integrate NHP models with AI-powered behavioral analytics

Who Should Attend?

This webinar may be relevant to professionals working in:

Translational medicine scientists
Preclinical pharmacology and efficacy study teams
CNS, neurodegeneration, and gene therapy researchers
Pain, pruritus, dermatology, and immunology researchers
Scientists working with NHP disease models and behavioral endpoints
Biotech and pharma teams developing therapies requiring functional efficacy readouts
CRO outsourcing managers evaluating advanced NHP study platforms
Data science and AI teams applying computer vision to preclinical research

What You Will Learn

3D NHP tracking

How high-fidelity 3D NHP tracking can be applied to real preclinical drug development challenges

NHP studies

How to design NHP studies with quantitative behavioral endpoints for more objective efficacy evaluation

AI-based behavioral analysis

How AI-based behavioral analysis can reduce manual workload, minimize observer bias, and improve data consistency

one-stop solution

How Prisys and Bayone integrate NHP disease models, behavioral study design, multi-view data acquisition

Speakers

David S. Wong

BD Manager, Asia Pacific, ClearPoint Neuro

David Wong has been the Asia Pacific Business Development Manager and on the Biologics & Drug Delivery Team at ClearPoint Neuro for 4 years. He has been working with clinical trials and regulatory projects in addition to handling commercial responsibilities in Asia, Oceania, and North America throughout his nearly 20-year career in the medical device space. Prior to that, he worked in the pharmaceutical industry. David has a master's in biotechnology from the Johns Hopkins University.

Message Presenter

James Song

General Manager, PRISYS Biotech

As General Manager of Prisys Biotech, James Song leverages 20 years of experience in NHP pharmacology and disease modeling to accelerate the transition from lab to clinic. He is a specialist in navigating the complexities of translational medicine, with a proven track record in managing high-value asset restructuring and forging strategic international alliances. Under his leadership, Prisys has strengthened its global footprint through sophisticated laboratory infrastructure, unique NHP models, and integrated NHP breeding operations.

Message Presenter